Whole-body MRI and PET/CT can miss many metastases
German researchers were stunned to discover that whole-body staging of patients with recently diagnosed malignancies using either MRI or PET/CT could miss a substantial number of metastatic lesions. They released their data at the 2007 RSNA meeting.
German researchers were stunned to discover that whole-body staging of patients with recently diagnosed malignancies using either MRI or PET/CT could miss a substantial number of metastatic lesions. They released their data at the 2007 RSNA meeting.
Dr. Florian Vogt and colleagues at the University Hospital of Essen enrolled 60 consecutive patients who underwent whole-body 1.5T MRI and whole-body FDG-PET/CT for staging of regional and distant melanoma metastases after primary tumor resection. Fifty-six patients completed the mean follow-up of 748 days. The researchers found that a significant number of patients initially staged as negative eventually proved to have undetected metastatic disease.
Another research group from Essen led by Dr. Gerald Antoch also evaluated the accuracy of whole-body FDG-PET/CT and whole-body MRI for staging and detection of bone metastases in 55 patients with melanoma and 54 with non-small cell lung cancer. The investigators found that, despite their accuracy for detection and staging, both tests yielded a significant rate of false negatives.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.
